NASDAQ:RARE - Ultragenyx Pharmaceutical Stock Price, Forecast & News

Ultragenyx Pharmaceutical's stock was trading at $45.35 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Since then, RARE shares have decreased by 6.6% and is now trading at $42.36. View which stocks have been mosted impacted by Coronavirus.

10 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Ultragenyx Pharmaceutical in the last year. There are currently 1 hold rating and 9 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Ultragenyx Pharmaceutical.

Ultragenyx Pharmaceutical is scheduled to release its next quarterly earnings announcement on Monday, May 4th 2020. View our earnings forecast for Ultragenyx Pharmaceutical.

Ultragenyx Pharmaceutical Inc (NASDAQ:RARE) announced its quarterly earnings data on Thursday, February, 13th. The biopharmaceutical company reported ($1.62) earnings per share (EPS) for the quarter, missing the Zacks' consensus estimate of ($1.61) by $0.01. The biopharmaceutical company had revenue of $35.59 million for the quarter, compared to analysts' expectations of $32.31 million. Ultragenyx Pharmaceutical had a negative net margin of 388.30% and a negative return on equity of 52.36%. View Ultragenyx Pharmaceutical's earnings history.

Ultragenyx Pharmaceutical updated its FY 2019 IntraDay earnings guidance on Monday, January, 13th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $102-104 million, compared to the consensus revenue estimate of $100.68 million.

10 brokers have issued twelve-month price objectives for Ultragenyx Pharmaceutical's shares. Their forecasts range from $70.00 to $87.00. On average, they anticipate Ultragenyx Pharmaceutical's share price to reach $78.13 in the next year. This suggests a possible upside of 84.4% from the stock's current price. View analysts' price targets for Ultragenyx Pharmaceutical.

News headlines about RARE stock have trended positive on Saturday, InfoTrie Sentiment reports. InfoTrie identifies positive and negative news coverage by analyzing more than six thousand news and blog sources. The firm ranks coverage of companies on a scale of -5 to 5, with scores closest to five being the most favorable. Ultragenyx Pharmaceutical earned a coverage optimism score of 2.4 on InfoTrie's scale. They also assigned headlines about the biopharmaceutical company a news buzz of 0.0 out of 10, indicating that recent news coverage is extremely unlikely to have an effect on the company's share price in the near term. View the latest news aboutUltragenyx Pharmaceutical.

Ultragenyx Pharmaceutical saw a increase in short interest in the month of March. As of March 13th, there was short interest totaling 6,949,400 shares, an increase of 6.9% from the February 27th total of 6,500,000 shares. Based on an average daily trading volume, of 478,200 shares, the days-to-cover ratio is presently 14.5 days. Approximately 12.8% of the company's shares are sold short. View Ultragenyx Pharmaceutical's Current Options Chain.

Some companies that are related to Ultragenyx Pharmaceutical include Ono Pharmaceutical (OPHLF), Teva Pharmaceutical Industries (TEVA), Elanco Animal Health (ELAN), Beigene (BGNE), Sarepta Therapeutics (SRPT), Mylan (MYL), Catalent (CTLT), Ionis Pharmaceuticals (IONS), Dr.Reddy's Laboratories (RDY), Perrigo (PRGO), ACADIA Pharmaceuticals (ACAD), Jazz Pharmaceuticals (JAZZ), Bausch Health Companies (BHC), Ascendis Pharma A/S (ASND) and Horizon Therapeutics (HZNP).

Based on aggregate information from My MarketBeat watchlists, some companies that other Ultragenyx Pharmaceutical investors own include Gilead Sciences (GILD), Exelixis (EXEL), Portola Pharmaceuticals (PTLA), TG Therapeutics (TGTX), Sangamo Therapeutics (SGMO), Crispr Therapeutics (CRSP), GALAPAGOS NV/S (GLPG), Intercept Pharmaceuticals (ICPT), Netflix (NFLX) and GW Pharmaceuticals PLC- (GWPH).

Ultragenyx Pharmaceutical trades on the NASDAQ under the ticker symbol "RARE."

Ultragenyx Pharmaceutical's stock is owned by a variety of retail and institutional investors. Top institutional shareholders include Capital Research Global Investors (11.01%), Capital International Investors (10.46%), Capital World Investors (5.60%), State Street Corp (3.81%), FMR LLC (3.16%) and Alliancebernstein L.P. (2.68%). Company insiders that own Ultragenyx Pharmaceutical stock include Emil D Kakkis, Karah Herdman Parschauer, Matthew K Fust, Shalini Sharp, Theodore Alan Huizenga and William Aliski. View institutional ownership trends for Ultragenyx Pharmaceutical.

RARE stock was sold by a variety of institutional investors in the last quarter, including FMR LLC, UBS Group AG, Capital Bank & Trust Co, Rafferty Asset Management LLC, Capital International Inc. CA, Candriam Luxembourg S.C.A., Cubist Systematic Strategies LLC, and Laurion Capital Management LP. Company insiders that have sold Ultragenyx Pharmaceutical company stock in the last year include Karah Herdman Parschauer, and Theodore Alan Huizenga. View insider buying and selling activity for Ultragenyx Pharmaceutical.

RARE stock was purchased by a variety of institutional investors in the last quarter, including Capital World Investors, Norges Bank, Franklin Resources Inc., Franklin Resources Inc., Alliancebernstein L.P., EcoR1 Capital LLC, First Trust Advisors LP, and Macquarie Group Ltd.. View insider buying and selling activity for Ultragenyx Pharmaceutical.

Shares of RARE can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of RARE stock can currently be purchased for approximately $42.36.

Ultragenyx Pharmaceutical has a market capitalization of $2.45 billion and generates $103.71 million in revenue each year. The biopharmaceutical company earns $-402,730,000.00 in net income (profit) each year or ($7.36) on an earnings per share basis.  View additional information about Ultragenyx Pharmaceutical.

The official website for Ultragenyx Pharmaceutical is http://www.ultragenyx.com/.

Ultragenyx Pharmaceutical's mailing address is 60 Leveroni Court, Novato CA, 94949. The biopharmaceutical company can be reached via phone at 415-483-8800 or via email at [email protected]